50 Stocks Moving In Tuesday's Mid-Day Session

Gainers

• Pioneer Power Solutions (NASDAQ:PPSI) shares jumped 235.7% to $5.27.
• Comstock Holding Companies, Inc. (NASDAQ:CHCI) gained 31% to $3.3389.
• Alteryx, Inc. (NYSE:AYX) climbed 26.4% to $143.98 after the company raised its sales guidance for the third quarter and announced Mark Anderson as new CEO.
• Westwater Resources, Inc. (NASDAQ:WWR) shares gained 26.1% to $10.44 after jumping over 87% on Monday. The company holds minerals rights for lithium and uranium deposits and strength appears related to momentum in lithium names amid EV battery interest.
• Piedmont Lithium Limited (NASDAQ:PLL) shares climbed 25.5% to $43.50. Piedmont Lithium shares jumped around 33% on Monday on continued strength after the company in late September announced it signed a sales agreement with Tesla.
• China Recycling Energy Corporation (NASDAQ:CREG) gained 22% to $4.27.
• TransAct Technologies Incorporated (NASDAQ:TACT) climbed 21.5% to $6.20 after the company raised its Q3 sales guidance.
• IKONICS Corporation (NASDAQ:IKNX) gained 19.2% to $3.98.
• Lightbridge Corporation (NASDAQ:LTBR) rose 18.2% to $4.825.
• Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) surged 18.1% to $18.71 after reporting data from Phase 2 trial of mavrilimumab in giant cell arteritis. The trial achieved both the primary and secondary efficacy endpoints with statistical significance.
• ReneSola Ltd (NYSE:SOL) gained 16% to $2.4698. ReneSola, last month, priced 2.5 million ADS offering at $2 per ADS.
• XpresSpa Group, Inc. (NASDAQ:XSPA) shares rose 15.4% to $2.6050 after gaining around 18% on Monday.
• Polar Power, Inc. (NASDAQ:POLA) jumped 14.9% to $4.375.
• Cogent Biosciences Inc. (NASDAQ:COGT) gained 14.9% to $2.70.
• Humanigen, Inc. (NASDAQ:HGEN) jumped 14.8% to $13.94. Humanigen, on Friday, issued updates on Lenzilumab in COVID-19 program.
• Group 1 Automotive, Inc. (NYSE:GPI) rose 14.7% to $117.00 after the company issued Q3 preliminary EPS above analyst estimates and announced a $200 million buyback. The company also said it intends to reinstate its dividend.
• Jaguar Health, Inc. (NASDAQ:JAGX) gained 14.6% to $0.3553 after the company announced it has met the financial condition for the sale of royalty rights for Mytesi.
• Neuronetics, Inc. (NASDAQ:STIM) gained 14.6% to $5.93. BTIG reiterated Neuronetics with a Buy and raised the price target from $6 to $10.
• TOMI Environmental Solutions, Inc. (NASDAQ:TOMZ) gained 13.4% to $9.70 after gaining over 15% on Monday. TOMI Environmental Solutions recently reported uplisting to the Nasdaq Capital Market.
• DBV Technologies S.A. (NASDAQ:DBVT) rose 10% to $1.8150.
• Naked Brand Group Limited (NASDAQ:NAKD) shares rose 8.5% to $0.1232 as the company’s subsidiary, Bendon, entered into a settlement deal with Timothy Connell, William Gibson and Ivory Castle.
• Gamida Cell Ltd. (NASDAQ:GMDA) rose 8.1% to $4.54 after the company announced its Phase 3 clinical study of Omidubicel met all three of its secondary endpoints.
• Emerald Holding, Inc. (NYSE:EEX) shares rose 7.9% to $2.50 after the company announced it authorized a $20 million buyback program.
• Xtant Medical Holdings, Inc. (NASDAQ:XTNT) rose 7.8% to $1.6388 after the company announced it has regained compliance with the NYSE American continued listing standards. Xtant Medical shares climbed over 91% on Friday after the company announced the closing of debt restructuring.
• Invitae Corporation (NYSE:NVTA) gained 7.2% to $48.67 after it was announced Taysha Gene Therapy and the company partnered to enabled rapid access to genetic testing and earlier diagnosis of patients with CNS disease and large-market indications.
• Himax Technologies, Inc. (NASDAQ:HIMX) rose 7% to $3.7033 following strong preliminary results for the third quarter.
• ChromaDex Corporation (NASDAQ:CDXC) rose 6.6% to $4.34. ChromaDex highlighted publicatoin of study results showing 'nutritional protocol including nicotinamide riboside plus standard of care reduces recovery time in COVID-19 patients by nearly 30%.'
• Tata Motors Limited (NYSE:TTM) rose 6.6% to $9.81.
• BioNTech SE (NASDAQ:BNTX) rose 6.5% to $85.88. BioNTech and Pfizer reported the initiation of rolling submission to the EMA for SARS-CoV-2 vaccine candidate BNT162b2.
• Can Fite Biopharma ADR (NYSE:CANF) gained 5.6% to $1.85 after an independent data monitoring committee recommended the company to continue with Phase III psoriasis study.
• Trinseo S.A. (NYSE:TSE) gained 4% to $28.61 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $28 to $35 per share.

Check out these big penny stock gainers and losers

Losers

• Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares dipped 36.5% to $1.20 after the company announced its Phase 2b study of Lenabasum for treatment of cystic fibrosis did not meet the primary endpoint.
• Miragen Therapeutics, Inc. (NASDAQ:MGEN) fell 21.1% to $0.60 after the company announced that it conducted an internal review of preliminary topline data from its Phase 2 SOLAR clinical trial of cobomarsen in patients with Cutaneous T-Cell Lymphoma. The press release said preliminary data in 37 patients suggest that cobomarsen lacks a compelling result for the study's primary endpoint.
• Axovant Gene Therapies Ltd. (NASDAQ:AXGT) fell 21% to $4.4501. Axovant reported positive six-month follow-up data from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy.
• Palomar Holdings, Inc. (NASDAQ:PLMR) shares fell 19.4% to $87.77. Palomar Holdings said it expects pretax catastrophe losses of $34 million to $38 million, net of reinsurance, during the third quarter.
• Hyliion Holdings Corp. (NYSE:HYLN) dropped 13.4% to $33.90. On Friday, Hyliion shares dropped 12% in first day of post-SPAC merger trading.
• Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell 12.5% to $28.05. Following a recent Type B meeting with the FDA, Iovance Biotherapeutics said it has not been able to agree with the FDA on the required potency assays to fully define its tumor-infiltrating lymphocyte therapy lifileucel in metastatic melanoma, which is required as part of a BLA submission. Wells Fargo downgraded Iovance Biotherapeutics from Overweight to Equal-Weight and lowered the price target from $49 to $29.
• Social Capital Hedosophia Holdings Corp. III (NYSE:IPOC) fell 12% to $11.17. Alphabet and Sequoia-backed insurance startup Clover Health plans to go public via a merger with blank check company Social Capital Hedosophia Holdings Corp. III, reports the New York Times.
• ProPhase Labs, Inc. (NASDAQ:PRPH) dipped 11.8% to $6.08. ProPhase Labs recently announced plans to explore the acquisition of one or more CLIA accredited labs suitable for COVID-19 and other testing.
• Artelo Biosciences, Inc. (NASDAQ:ARTL) fell 11% to $0.97 after surging over 26% on Monday. Artelo Biosciences, last week, received Ethics Committee approval in the UK to commence its Phase I/II study of ART27.13.
• Nam Tai Property Inc. (NYSE:NTP) dropped 10.3% to $6.19. Nam Tai Property shares tumbled 26% on Monday as the company raised $170 million through private placement transaction.
• Inpixon (NASDAQ:INPX) fell 9.8% to $1.1099. Inpixon yesterday announced plans to buy Nanotron for $8.7 million.
• Lithium Americas Corp. (NYSE:LAC) shares dipped 9.4% to $14.37.
• JinkoSolar Holding Co., Ltd. (NYSE:JKS) dropped 7.9% to $ 44.51.
• Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) shares fell 7.7% to $38.51 after the company reported it received a Refusal to File letter from the FDA regarding the Biologics License Application for omburtamab for the treatment of patients with neuroblastoma.
• Greenpro Capital Corp. (NASDAQ:GRNQ) shares fell 6.4% to $1.7410. Greenpro Capital shares jumped over 70% on Monday after the company reported it intends to incubate a satellite communication venture.
• Pacific Drilling S.A. (NYSE:PACD) fell 6.4% to $0.2751 after rising 5% on Monday.
• Logitech International S.A. (NASDAQ:LOGI) fell 5.6% to $76.28. Logitech is expected to release quarterly earnings on October 19.
• LM Funding America, Inc. (NASDAQ:LMFA) fell 5.3% to $0.5672 after declining around 8% on Monday.
• PIMCO Dynamic Income Fund (NYSE:PDI) fell 4.8% to $24.62 after the company announced a public offering of 3 million shares of common stock.